The Pharma Data

DECEMBER 3, 2020

He also served as CFO at Aralez Pharmaceuticals Inc. Prior to UroGen, Pfreudschuh was the CFO of Sucampo Pharmaceuticals Inc., Monti has served as president and CEO of Pherin Pharmaceuticals. Bradshaw most recently served as CSO for Arrowhead Pharmaceuticals. and spent 11 years at Sanofi in a variety of financial roles.

Pharmaceuticals 52

Pharmaceuticals Clinical Development Medical Schools Pharmacy 52

The Pharma Data

DECEMBER 17, 2020

Hartfield previously served as CEO of Vitae Pharmaceuticals prior to its acquisition by Allergan. X4 Pharmaceuticals – Diego Cadavid was named chief medical officer of Boston-based X4 Pharmaceuticals. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

The Pharma Data

JUNE 28, 2021

“Bayer is focused on addressing the various medical needs of cancer patients, providing treatments that improve patient outcomes throughout the different stages of the disease,” said Robert LaCaze, Member of the Executive Committee of the Pharmaceuticals Division and Head of the Oncology Strategic Business Unit at Bayer.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

The Pharma Data

JANUARY 21, 2021

Caggiano joins Evolve Biologics after most recently serving as CEO of Dendreon Pharmaceuticals LLC. Among his earlier leadership roles in the biotech, pharmaceutical and medical device industries, Caggiano directed the divestiture of Allergan’s LAP-BAND to Apollo Endosurgery in 2013. Abbott Laboratories and TAP Pharmaceuticals.

Laboratories 52

Laboratories Pharmaceuticals Clinical Development Engineering 52

The Pharma Data

APRIL 6, 2022

” Integrating Pharmaceuticals and Oncology business units. Novartis will integrate the Pharmaceuticals and Oncology business units and create two separate commercial organizations with a stronger geographic focus – Innovative Medicines US and Innovative Medicines International.

International 52

International Pharmaceuticals Drug Development Marketing 52

The Pharma Data

OCTOBER 14, 2020

. Potential Development of Human Monoclonal Antibody Therapeutics to SARS-CoV-2. 15, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. President and Chief Executive Officer of Tonix Pharmaceuticals. 2018) PLoS One. About Tonix Pharmaceuticals Holding Corp. CHATHAM, N.J.,

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

The Pharma Data

APRIL 29, 2022

Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Evrysdi was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by the U.S. Enrolment for Part 2 was completed in November 2018.

Treatment 52

Treatment Clinical Trials Trials Clinical Development 52

The Pharma Data

NOVEMBER 10, 2020

Growing into a biopharmaceutical company, Innovent has built an integrated platform covering from drug discovery, CMC, clinical development and commercialization. Dr. Liu shared his over 30 years of R&D experience in drug development both in the global pharmaceutical companies and world renowned scientific research institutions.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

PPD

DECEMBER 14, 2023

In this blog, we’ll explore the benefits associated with employing global resources across time zones for FSP engagements and how PPD ® FSP solutions utilize different regions to drive more efficient clinical development operations.

Clinical Development 52

Clinical Development Clinical Trials International Trials 52

The Pharma Data

MAY 31, 2022

More than 5,000 patients have now been treated worldwide with Evrysdi in clinical trials, compassionate use or real-world settings. Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Food and Drug Administration in 2017.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

Metabolite Tales Blog

JANUARY 26, 2023

Since CYP2D6 displays a genetic polymorphism, resulting in large interindividual and ethnic differences, pharmaceutical companies have a motivation to design drug candidates that avoid metabolism by this CYP, something that seems to have come to fruition in this set of new drug approvals. Sugano, 2018. Curr Drug Metab. 20(4): 254-265.

Small Molecule 52

Small Molecule FDA Approval FDA Drugs 52

The Pharma Data

SEPTEMBER 19, 2020

Basel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Treatment 52

Treatment Disease Therapies Pharmaceuticals 52

The Pharma Data

DECEMBER 15, 2020

The dual combination study was conducted under a clinical trial collaboration agreement signed in 2016 between BioLineRx and MSD, through a subsidiary, where MSD provided KEYTRUDA ® and BioLineRx was the study sponsor and owns all rights to motixafortide. a company that supports oncology drug development. of new cancer cases.

Clinical Trials 40

Clinical Trials Trials Treatment Therapies 40

The Pharma Data

SEPTEMBER 2, 2020

The Phase III clinical development programme for ENSPRYNG includes two studies: SAkuraStar and SAkuraSky. In addition, it was granted Breakthrough Therapy Designation for the treatment of NMOSD by the FDA in December 2018. About Roche in neuroscience Neuroscience is a major focus of research and development at Roche.

Clinical Trials 52

Clinical Trials Disease Treatment Therapies 52

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

PPD

APRIL 14, 2025

Medical researchers and practitioners see in their own patients how these ailments interconnect and overlap, as do the pharmaceutical and biotech companies working to develop GLP-1 therapeutics. It is worth noting that trial ran from 2018 to 2021, before the U.S.

Clinical Trials 52

Clinical Trials Trials Clinical Development Disease 52

Drug Target Review

JUNE 21, 2023

Strikingly, a strong genetic link between target and disease biology is emerging as a predictor for success in clinical trials. 2,3 This is exemplified by drugs that target disease-specific genes or genetically distinct patient subsets which are more likely to succeed in demonstrating efficacy in clinical development.

Disease 111

Disease Clinical Trials Therapies Science 111

The Pharma Data

OCTOBER 26, 2020

On 14 May 2018, the Company announced a collaboration with GlobalCo to work on its CDX antibody. This additional extension of the collaboration will allow us to choose the best CDX antibody for pre-clinical and clinical development.” Enquiries: Hemogenyx Pharmaceuticals plc.

Pharmaceuticals 40

Pharmaceuticals Engineering Disease Pharmaceutical Companies 40

The Pharma Data

JANUARY 25, 2021

26, 2021 /PRNewswire/ — Asieris Pharmaceuticals announced today that the company has entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to exclusively register and commercialize Hexvix® in Mainland China and Taiwan. SHANGHAI , Jan. ” About Photocure ASA. About Non-Muscle Invasive Bladder Cancer (NMIBC).

Licensing 40

Licensing Licensing Clinical Development Pharmaceutical Companies 40

The Pharma Data

SEPTEMBER 9, 2020

In addition, it was granted Breakthrough Therapy Designation for the treatment of NMOSD by the FDA in December 2018. The Phase III clinical development programme for ENSPRYNG includes two studies: SAkuraStar and SAkuraSky. About Roche in neuroscience Neuroscience is a major focus of research and development at Roche.

Treatment 52

Treatment Disease Therapies FDA 52

The Pharma Data

AUGUST 16, 2020

The Phase III clinical development programme for ENSPRYNG includes two studies: SAkuraStar and SAkuraSky. In addition, it was granted Breakthrough Therapy Designation for the treatment of NMOSD by the FDA in December 2018. Neuroscience is a major focus of research and development at Roche. About Roche in neuroscience.

FDA Approval 52

FDA Approval FDA Clinical Trials Treatment 52

The Pharma Data

JANUARY 24, 2021

Management of the Company believe that the proposed acquisition will strengthen PharmaDrug’s product pipeline, intellectual property portfolio and pharmaceutical development expertise. Sairiyo is currently focused on advancing the clinical development of Cepharanthine to treat rare cancer diseases.

FDA 52

FDA Drugs Clinical Development Disease 52

The Pharma Data

NOVEMBER 8, 2020

Supernus Pharmaceuticals’ SPN-812 for ADHD. Supernus Pharmaceuticals has a target action date of November 8, 2020 for SPN-812 for the treatment of attention deficit hyperactivity disorder (ADHD). Adamis Pharmaceuticals’ Zimhi for Opioid Overdose. Food and Drug Administration (FDA) in terms of PDUFA dates.

FDA 52

FDA Trials Therapies Pharmaceuticals 52

The Pharma Data

JANUARY 25, 2021

“ This marks our second strategic agreement with Asieris, a well-run and well-capitalized company that is executing ahead of plan on the clinical development of Cevira ®, which we licensed to them in July 2019. but with a healthcare system that is still developing. 75% of all bladder cancer cases occur in men.

Clinical Development 40

Clinical Development Licensing Licensing Production 40

The Pharma Data

MAY 18, 2021

The Phase III clinical development programme for ENSPRYNG includes two studies: SAkuraStar and SAkuraSky. In addition, it was granted Breakthrough Therapy Designation for the treatment of NMOSD by the FDA in December 2018. About Roche in neuroscience Neuroscience is a major focus of research and development at Roche.

Disease 40

Disease Treatment Therapies Pharmaceuticals 40

The Pharma Data

DECEMBER 13, 2020

Zai Labs obtained regional development and commercialization rights for the programs in mainland China, Hong Kong, Macau and Taiwan. Zai Lab is leading clinical development in its territory. “We Zai is strongly positioned to take advantage of a growing pharmaceutical market in this region.”.

FDA 52

FDA Biosimilars Clinical Trials Licensing 52

The Pharma Data

DECEMBER 27, 2020

million people misused prescription opioids in 2018, and many die every day from opioid-related drug overdoses. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. According to the US Department of Health and Human Services, 10.3

Trials 40

Trials Clinical Trials Pharmaceutical Companies Pharmaceuticals 40

LifeSciVC

APRIL 27, 2023

By the time Chapter 1 was nearing its end, Project Troubled Water, then Nimbus Discovery, became Nimbus Therapeutics as we took a further step to forward integrate into clinical development. The year was 2018, and the Board at Nimbus had agreed with our plan to re-invest in discovery and build out our internal pipeline.

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40

The Pharma Data

FEBRUARY 22, 2022

Then, she served on the Board of Directors of Capgemini for two years (2016-2018) before being appointed to her current position as Group CFO. Antoine Yver took over in 2021 as Chief Medical Officer of Centessa Pharmaceuticals, Inc. He began his oncology development career at Rhône Poulenc Rorer Inc.

Clinical Trials 52

Clinical Trials DNA Science Clinical Development 52

The Pharma Data

JUNE 26, 2021

RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. You may also report side effects to Janssen Pharmaceuticals, Inc., for use in appropriate pediatric patients. The most common side effect of XARELTO ® was bleeding.

Doctors 52

Doctors Treatment Hospitals Clinical Trials 52

The Pharma Data

JANUARY 18, 2021

ZTlido ® was approved by the FDA on February 28, 2018. SEMDEXA is a trademark of Semnur Pharmaceuticals, Inc. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc. RTX has completed a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

The Pharma Data

JANUARY 14, 2021

This vision is what defines us and guides our research, clinical development and partnerships. Five Prime collaborates with leading global pharmaceutical companies and has therapies in pre-clinical and clinical development. For more information, please visit www.fiveprime.com. References. Data on file.

Trials 52

Trials Treatment Therapies Clinical Trials 52

The Pharma Data

JANUARY 13, 2021

14, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals, Inc. Tonix Pharmaceuticals Holding Corp. Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. CHATHAM, N.J.,

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

SEPTEMBER 27, 2020

Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics. Risdiplam was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively. In 2019, Roche invested CHF 11.7

FDA Approval 52

FDA Approval Pharmacokinetics Treatment Clinical Trials 52

Drug Target Review

APRIL 25, 2025

The Current Status and Use of Microphysiological Systems by the Pharmaceutical Industry: The International Consortium for Innovation and Quality Microphysiological Systems Affiliate Survey and Commentary. Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications.

Clinical Development 52

Clinical Development Small Molecule Drugs FDA Approval 52

The Pharma Data

DECEMBER 2, 2020

Previously, the company announced positive results of the previous Phase IIa induction study in UC in September 2018. HZI – Germany’s Helmholtz Centre for Infection Research (HZI) secured two awards worth up to $15 million from CARB-X to develop non-traditional approaches against antibiotic-resistant pathogens. in Mainland China.

Licensing 52

Licensing Licensing DNA Vaccine 52

The Pharma Data

NOVEMBER 22, 2020

Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. Islatravir is a promising antiviral candidate with evidence from ongoing clinical trials to support its development as a once-monthly oral PrEP agent.

Trials 52

Trials Clinical Trials International Production 52